
    
      This is a multi-center, open-label, randomized, Phase II study.

      Patients will be treated either with arm A or B

        -  Arm A: Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses.

        -  Arm B: Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses combined with
           weekly subcutaneous injections of Epoetin beta (60,000 Units/w).

      Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.

      Maintenance: responders will continue to follow the corresponding treatment arm until relapse
      occurs; non responders at Evaluation of response at the end of 4 months according to IWG 2006
      and IWG 2000 criteria.

      in arm A will be considered in failure of treatment and the introduction of Epoetin beta is
      at the discretion of the physician.

      The patients will be followed every 3 months for 12 months
    
  